Member Info for HereforHemo

No ifs or buts “To take Hemo CAR-T to clinical trials” They sound very confident to me :)

https://twitter.com/hemogenyxpharma/status/1489582141302353920?s=21

If it’s over 4p I’ll be there.

Mr I I think that’s a perfectly reasonable expectation.

Mr India whilst your negativity doesn’t bother me, as I understand your frustration, I’m afraid Brewsky is right in what he says. If you think you’re going to make your 70k back on the forthcoming RNS (which I expect to confirm a positive meeting with the FDA) I think you’re sadly mistaken. Now, if you want to look at the next RNS, confirming IND application and the following RNS confirming FDA approval for clinical trials THEN you can start thinking about getting your money back and even begin to turn some profit. IF you can wait until clinical proof of concept, obviously not without risk, then you can look to earn some serious profit. Obviously I’m focusing on CAR-T but that’s not to say there might be other announcements on CDX or CBR, or maybe a non dilutive funding agreement to act as further catalysts. But the bottom line is you can moan and whine as much as you want, everyday even, but it won’t change the fact you have to wait in this game, with this company and this sector. If as it seems waiting and being patient is beyond you, which very much seems the case, then as I’ve said to you before, man up, take responsibility for your mistake take your loss and and sell up. I regret to say you won’t be missed.

The same team and the same individuals that are working with HEMO. We have the world leaders in CAR-T and all their expertise to help Vlad into clinical trials.

https://twitter.com/carlhjune/status/1488936351785308160?s=21

And let’s not forget high level politicians are already aware of Hemogenyx.

https://twitter.com/hemogenyxpharma/status/1425216924301107209?s=21

Mr India, it’s probably going to take more than one RNS for the major rerate you’re looking for. First out, positive feedback from the FDA meeting, next the IND application, followed by FDA approval for clinical trials. Just my opinion.

See previous post. Up up and away lol

Decent buys coming in as we approach the FDA meeting, that is if it’s not been held already. Wouldn’t be surprised if we break the 2p barrier in the next couple of weeks, and I don’t expect it to fall below it again once achieved.

Only a couple of months before Hemogenyx move into their new laboratory. The fact Vlad is quoted saying they can upscale when they grow out of it says everything regarding the confidence they have on their product candidates. Only patience required in my opinion.

https://bostonrealestatetimes.com/in-substantial-growth-move-hemogenyx-pharmaceuticals-moves-to-mink-building-in-new-york-city/

Considering you can wait many years for a company to move from a pre-clinical to a clinical company I think the ‘jam tomorrow’ statement (whilst accurate) is a blink of an eye in pharmaceutical terms for Hemogenyx. It’s highly probable Hemogenyx will have at least one if not two product candidates entering human trials this year. Furthermore if, as I expect, the pre-IND meeting with the FDA goes well this month, not only can we expect a rapid IND application but an expedited approval as well. Hemogenyx could well be a clinical company by early summer. If that is ‘jam tomorrow’ and too long for you to wait, you really have invested in the wrong sector. Just my opinion.

https://www.fda.gov/media/86377/download

Why would any reasonable individual be short on any stock that is trading at near record lows? The only way HEMO can realistically go is higher and that will happen when volume returns which in turn will happen on news. Maybe a couple of weeks or a bit longer but should be worth the wait. Imo.

High stakes..luckily for Hemogenyx it’s the majors who bear the ongoing risk.

https://twitter.com/genbio/status/1487507094815363078?s=21

Anyone got any thoughts on what CBR is going to be based on? I have a hunch that it’s CAR-NK. Firstly NK cells can directly kill cells infected with either viral or other intracellular pathogens, and secondly there are already a plethora of CAR-T therapies and as Hemogenyx state this is a totally unique approach in the market, I just feel it’s got to be based on something leading edge. Thoughts welcome.

https://www.frontiersin.org/articles/10.3389/fimmu.2021.622306/full

I think it may be even more exciting than CAR-T. I think they may have released Cytotoxic granules to trigger target cell death, in other words be using CAR-NK.

After wobbling a bit of late I thought I’d go through all the RNS’s and Vlads interviews last night to reaffirm to myself why I invested. I must say it’s got me very bullish of the stock again. For Vlad to be moving into such a big laboratory in a couple of months, with the capability to make their own CAR demonstrates a high degree of internal confidence in HEMO CAR-T and SAFE CAR-T, especially knowing how frugal Vlad is in spending money. I understand HEMO are going to discuss fast tracking this candidate into clinical trials although not sure as yet whether it’ll be assigned as a breakthrough therapy but either way I expect it to move quickly into trials after the IND application. Upon application I think volume will return and we’ll start the long road back up, after all it’s potentially a billion dollar candidate. Add in CBR and a CDX update it must be a profitable couple of quarters for holders, in my opinion anyway. I’m now comfortable again, holding and waiting. Tick tock.

Brewsky JHFH Thx for the responses. I’m feeling a lot more confident things could happen sooner than I thought, here’s hoping anyway. In the meantime I’ll try to keep my frustration in check lol.

Strange I’m meant to be selling when I’ve only recently topped up lol. You ask what I’d like Vlad to tell me, well four things really.
1. Where’s the CBR update that he promised was ‘soon’ back in June?
2. Did the FDA agree to the pre-IND meeting and if so when is it?
3. People like yourself are saying pre-clinical work is complete and clinical trials are soon, yet you stated that when you have the pre-IND meeting CAR-T would be 80% complete. Is this no longer the case, are pre-clinical studies complete?
4. You stated a CAR-T IND application would be made ‘in the summer’. Has this now been brought forward because that’s months away and would indicate people are selling if they mentioned it so can you clarify?
Don’t think that’s too much to ask, do you?

Mr India in answer to your questions, imo people are selling as Vlad is still running this like it’s a private company, in stealth mode telling investors nothing.
And although investors expect an update on the FDA meeting there are no guarantees. It’s quite possible we hear nothing for months, certainly based on previous HEMO experience. So if you need the money or think something will move sooner, just take the loss and move on. Else wait it out like everyone else.

JHFH HEMO are not at the IND stage hence why no one is buying it yet. When they submit an IND application they will be at the IND stage, could be weeks away but it could be months away. Time will tell.